Improvement of a stability-indicating method by Quality-by-Design versus Quality-by-Testing: A case of a learning process

被引:45
作者
Hubert, C. [1 ]
Lebrun, P. [1 ]
Houari, S. [1 ]
Ziemons, E. [1 ]
Rozet, E. [1 ]
Hubert, Ph. [1 ]
机构
[1] Univ Liege ULg, Dept Pharm, CIRM, Analyt Chem Lab,CHU, B-4000 Liege, Belgium
关键词
Stability-indicating method; Quality-by-Design; Design Space; Robustness; Learning process; LIQUID-CHROMATOGRAPHY; SPACE; OPTIMIZATION; FORMULATIONS; VALIDATION; DRUGS; ASSAY;
D O I
10.1016/j.jpba.2013.09.026
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The understanding of the method is a major concern when developing a stability-indicating method and even more so when dealing with impurity assays from complex matrices. In the presented case study, a Quality-by-Design approach was applied in order to optimize a routinely used method. An analytical issue occurring at the last stage of a long-term stability study involving unexpected impurities perturbing the monitoring of characterized impurities needed to be resolved. A compliant Quality-by-Design (QbD) methodology based on a Design of Experiments (DoE) approach was evaluated within the framework of a Liquid Chromatography (LC) method. This approach allows the investigation of Critical Process Parameters (CPPs), which have an impact on Critical Quality Attributes (CQAs) and, consequently, on LC selectivity. Using polynomial regression response modeling as well as Monte Carlo simulations for error propagation, Design Space (DS) was computed in order to determine robust working conditions for the developed stability-indicating method. This QbD compliant development was conducted in two phases allowing the use of the Design Space knowledge acquired during the first phase to define the experimental domain of the second phase, which constitutes a learning process. The selected working condition was then fully validated using accuracy profiles based on statistical tolerance intervals in order to evaluate the reliability of the results generated by this LC/ESI-MS stability-indicating method. A comparison was made between the traditional Quality-by-Testing (QbT) approach and the QbD strategy, highlighting the benefit of this QbD strategy in the case of an unexpected impurities issue. On this basis, the advantages of a systematic use of the QbD methodology were discussed. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:401 / 409
页数:9
相关论文
共 26 条
[1]  
[Anonymous], 2005, QUALITY RISK MANAGEM
[2]  
[Anonymous], 2006, INT C HARM TECHN REQ, V14
[3]  
[Anonymous], 2009, Q8 R2 PHARM DEV
[4]  
Borman P., 2007, Pharm. Technol, V31, P142
[5]   Chemometric-assisted method development in reversed-phase liquid chromatography [J].
Cela, R. ;
Ordonez, E. Y. ;
Quintana, J. B. ;
Rodil, R. .
JOURNAL OF CHROMATOGRAPHY A, 2013, 1287 :2-22
[6]  
Debrus B, 2013, LC GC EUR, V26, P370
[7]   Innovative high-performance liquid chromatography method development for the screening of 19 antimalarial drugs based on a generic approach, using design of experiments, independent component analysis and design space [J].
Debrus, B. ;
Lebrun, P. ;
Kindenge, J. Mbinze ;
Lecomte, F. ;
Ceccato, A. ;
Caliaro, G. ;
Mbay, J. Mavar Tayey ;
Boulanger, B. ;
Marini, R. D. ;
Rozet, E. ;
Hubert, Ph. .
JOURNAL OF CHROMATOGRAPHY A, 2011, 1218 (31) :5205-5215
[8]   Improved quality-by-design compliant methodology for method development in reversed-phase liquid chromatography [J].
Debrus, Benjamin ;
Guillarme, Davy ;
Rudaz, Serge .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2013, 84 :215-223
[9]   Application of new methodologies based on design of experiments, independent component analysis and design space for robust optimization in liquid chromatography [J].
Debrus, Benjamin ;
Lebrun, Pierre ;
Ceccato, Attilio ;
Caliaro, Gabriel ;
Rozet, Eric ;
Nistor, Iolanda ;
Oprean, Radu ;
Ruperez, Francisco J. ;
Barbas, Coral ;
Boulanger, Bruno ;
Hubert, Philippe .
ANALYTICA CHIMICA ACTA, 2011, 691 (1-2) :33-42
[10]   A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603) [J].
Gavin, Peter F. ;
Olsen, Bernard A. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 46 (03) :431-441